SynDevRx is located in Cambridge Massachusetts at the Cambridge Innovation Center. Our team is comprised of highly experienced drug development professionals with expertise in the critical areas of clinical trial design and management, process development, chemistry, manufacturing and controls (CMC), toxicology, pharmacology, and regulatory affairs.
We have efficiently moved our lead compound SDX-7320 from pre-clinical testing into Phase 1 human clinical trials for oncology. Our goal is to show clinical proof of concept for SDX-7320 and to leverage our proprietary polymer conjugation technology to create other novel molecules for oncology and metabolic diseases.
We believe that success comes from a balanced combination of leading technology and talented people with synergistic skills. Our combination of best-in-class compounds, top scientific advisors, and a team of experienced, senior drug development professionals will deliver high impact therapeutics to patients and high value to investors.
Lead Drug - SDX-7320
SynDevRx lead polymer conjugate SDX-7320 was designed as a best in class MetAP2 inhibitor for the treatment of cancer. SDX-7320 is a patented, novel polymer conjugate which releases a pharmacologically active novel small molecule fumagillol derivative in vivo.
In animal models, SDX-7320 has shown improved activity relative to other small molecule compounds from the fumagillin class.
NB: SynDevRx is not affiliated with Children's Hospital Boston, and has no development program associated with Children's Hospital.